Manipulation of meningeal lymphatic vasculature for brain and cns tumor therapy
AssigneeYale University
InventorsAkiko IWASAKI, Jean-Leon THOMAS, Eric SONG
Life of this patent
Estimating the term…
Loading patent…
AssigneeYale University
InventorsAkiko IWASAKI, Jean-Leon THOMAS, Eric SONG
Estimating the term…
A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistemamagna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.
A method of inducing lymphangiogenesis in the brain or central nervous system of a subject in need thereof, the method comprising administering to the subject an effective amount of a lymphangiogenesis inducer.
A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject in need thereof, the method comprising administering to the subject an effective amount of a lymphangiogenesis inducer.
A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a lymphangiogenesis inducer, wherein the cancer is in the brain or the central nervous system of the subject.
A pharmaceutical composition comprising a lymphangiogenesis inducer and an immunotherapeutic agent.
Dependencies are inferred from the claim text.